Levels of Drebrin A, and spines containing the protein, decline early in AD and animal models [32, 48, 49]; its upregulation by SPG302 is consistent with the formation of larger, mushroom-shaped spines and suggests a normalization of synaptic cytoskeletal function by the drug. This evidence concerns the gene DBN1 and Alzheimer disease.